替吉奥同步调强放疗治疗老年Ⅲ期非小细胞肺癌的临床观察

The clinical efficacy and safety of S-1 concurrent intensity modulated radiotherapy in the treatment of elderly patients with stage Ⅲ non-small cell lung cancer

目的替吉奥同步调强放疗治疗老年Ⅲ期非小细胞肺癌的临床疗效及安全性。方法选取我院2015年1月至2018年1月84例Ⅲ期非小细胞肺癌的患者,随机分为观察组和对照组,每组41例,观察组给予单纯调强放疗,对照组给予替吉奥同步调强放疗,分析两组患者的治疗效果及不良反应。结果观察组总有效率为71. 41%,临床控制率为90. 47%,对照组总有效率为88. 09%,临床控制率为95. 23%,对照组效果优于观察组,P <0. 05,具有统计学意义。结论替吉奥同步调强放疗治疗老年Ⅲ期非小细胞肺癌的临床疗效较好,毒副反应小,给药方便,耐受性好,值得临床推广应用。

Objective To evaluate the clinical efficacy and safety of S-1concurrent intensity modulated radiotherapy(IMRT)in the treatment of elderly patients with stageⅢnon-small cell lung cancer(NSCLC).Methods82patients with stageⅢnon-small cell lung cancer in our hospital from January2015to January2018were randomly divided into observation group and control group,41cases in each group.The observation group was treated with IMRT alone,while the control group was treated withS-1synchronous IMRT.The therapeutic effect and adverse reactions of the two groups were analyzed.Results The total effective rate of the observation group was71.41%,the clinical control rate was90.47%,the total effective rate of the control group was88.09%,and the clinical control rate was95.23%.The effect of the control group was better than that of the observation group,P<0.05,with statistical significance.Conclusion S-1simultaneous intensity modulated radiation therapy for elderly stageⅢnon-small cell lung cancer has good clinical efficacy,less toxicity and side effects,convenient administration and good tolerance,which is worthy of clinical application.